Seattle Genetics and Abbott have expanded their antibody-drug conjugate (ADC) collaboration under which Abbott will pay $25 million upfront for rights to use Seattle Genetics’ auristatin-based ADC technology for additional oncology targets. Seattle Genetics is also eligible to receive $220 million in potential milestone payments per target for predetermined development and commercial objectives, as well as royalties on worldwide sales of any resulting products under the collaboration. Under the...